Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
The DOI matches its Crossref record; 159 of the 160 references it cites were found in a registry or an index.
Abstract
Unlabelled The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) recommend that a marker of bone formation (serum procollagen type I N propeptide, s-PINP) and a marker of bone resorption (serum C-terminal telopeptide of type I collagen, s-CTX) are used as reference analytes for bone turnover markers in clinical studies.Introduction Bone turnover markers (BTM) predict fracture risk, and treatment-induced changes in specific markers account for a substantial proportion of fracture risk reduction. The aims of this report were to determine their clinical potential in the prediction of fracture risk and for monitoring the treatment of osteoporosis and to set an appropriate research agenda.Methods Evidence from prospective studies was gathered through literature review of the PUBMED database between the years 2000 and 2010 and the systematic review of the Agency for Healthcare Research and Quality up to 2001.Results High levels of BTMs may predict fracture risk independently from bone mineral density in postmenopausal women. They have been used for this purpose in clinical practice for many years, but there is still a need for stronger evidence on which to base practice. BTMs provide pharmacodynamic information on the response to osteoporosis treatment, and as a result, they are widely used for monitoring treatment in the individual. However, their clinical value for monitoring is limited by inadequate appreciation of the sources of variability, by limited data for comparison of treatments using the same BTM and by inadequate quality control. IOF/IFCC recommend one bone formation marker (s-PINP) and one bone resorption marker (s-CTX) to be used as reference markers and measured by standardised assays in observational and intervention studies in order to compare the performance of alternatives and to enlarge the international experience of the application of markers to clinical medicine.Conclusion BTM hold promise in fracture risk prediction and for monitoring treatment. Uncertainties over their clinical use can be in part resolved by adopting international reference standards.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have investigated the relationship between smoking and bone mass as measured by BMD, but the trend of research in this field is to use bone turnover markers to provide insight into the dynamics of bone turnover in metabolic bone disorders, monitor effectiveness of antiresorptive therapies, and predict the earlier risk of osteoporosis and fracture [93].”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [93]
In the citing paper
“Recently, the serum procollagen type I N-terminal propeptide (PINP) has been recommended as a standard marker for bone formation, while the carboxyl-terminal telopeptide of collagen type I (CTXI) has been recommended as a standard marker for bone resorption [68, 93, 95].”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [93]
In the citing paper
“Both markers are recommended by the International Osteoporosis Foundation and International Federation of Clinical Chemistry [93].”
From The Effect of Tobacco Smoking on Bone Mass: An Overview of Pathophysiologic Mechanisms (2018) · cites this paper as [93]
Citations
Cites
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026 · cited 4×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundInfluentialProfessor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“−59 −30 −58 Denosumab Cummings [98] 60 mg/6 months, s.”
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986 · cited 1×
“Zoledronate Black [97] 5 mg/year i.”
Self-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
Self-citationConsensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis
(1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90218-e · Cited by 2,874
Harris, S. T. (1999) · JAMA · doi:10.1001/jama.282.14.1344 · Cited by 2,475 · cited 1×
“Risedronate Harris [90] 5 mg/day −23”
Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., Cannata, J., Balogh, A., Lemmel, E.-M., Pors-Nielsen, S., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa022436 · Cited by 1,638
A reference standard for the description of osteoporosis
Kanis, J. A., McCloskey, E. V., Johansson, H., Oden, A., Melton, L. J., & Khaltaev, N. (2008) · Bone · doi:10.1016/j.bone.2007.11.001 · Cited by 1,234 · cited 3×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundSelf-citationDenosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Self-citationChesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., Kiel, D., LeBoff, M., Maricic, M., Miller, P., et al. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00490-3 · Cited by 1,122 · cited 1×
“Calcitonin Chesnut [83] 200 IU/day, intranasal −10 Strontium ranelate Meunier [84] 2 g/day +8 −12 Bruyère [85] −11”
Self-citationIncreased bone turnover in late postmenopausal women is a major determinant of osteoporosis
Dr. Garnero, P., Sornay-Rendu, E., Chapuy, M.-C., & Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110307 · Cited by 1,001 · cited 1×
“This increase is maintained for several decades after the menopause [30] and is associated with accelerated bone loss [31–39].”
BackgroundSelf-citationMarkers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study
Garnero, P., Hausherr, E., Chapuy, M.-C., Marcelli, C., Grandjean, H., Muller, C., Cormier, C., Bréart, G., Meunier, P. J., & Dr. Delmas, P. D. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650111021 · Cited by 989 · cited 3×
“For example, one study [50] reported that u-CTX predicted hip fracture in elderly women with a gradient of risk of 1.”
BackgroundResultSelf-citationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., Burlet, N., Cooper, C., Delmas, P. D., Reginster, J.-Y., Borgstrom, F., Rizzoli, R., & on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) · Osteoporosis International · doi:10.1007/s00198-008-0560-z · Cited by 776
Self-citationCummings, S. R., Karpf, D. B., Harris, F., Genant, H. K., Ensrud, K., LaCroix, A. Z., & Black, D. M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)01124-x · Cited by 752 · cited 1×
“For example, the change in spine BMD over 3 years explained only 11% of the reduction in spine fracture risk with alendronate [119], 18% for risedronate [120] and close to zero for raloxifene [121].”
BackgroundConsensus Development Conference: A Cross-Cultural Study
Larsen, J. K., & Rogers, E. M. (1984) · Knowledge · doi:10.1177/107554708400500406 · Cited by 751
Kopera, H., & Ziegler, R. (1989) · Klinische Wochenschrift · doi:10.1007/bf01719785 · Cited by 749
The Use of Biochemical Markers of Bone Turnover in Osteoporosis
Delmas, P. D., Eastell, R., Garnero, P., Seibel, M. J., & Stepan, J. (2000) · Osteoporosis International · doi:10.1007/s001980070002 · Cited by 722
Self-citationGarnero, P., Sornay-Rendu, E., Claustrat, B., & Delmas, P. D. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.8.1526 · Cited by 709 · cited 1×
“For example, s-OC is variously a strong [56, 62], moderate [55, 63], borderline [49, 50] or non-significant [47, 51, 58–60, 68] predictor of fracture risk.”
BackgroundSelf-citationGarnero, P. (1994) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.79.6.1693 · Cited by 707 · cited 6×
“Even closely related markers show different responses; for example, the response of free DPD to alendronate is modest or not present, but the total DPD changes as much as NTX [107].”
BackgroundInfluentialSelf-citationSiris, E. S., Harris, S. T., Rosen, C. J., Barr, C. E., Arvesen, J. N., Abbott, T. A., & Silverman, S. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.8.1013 · Cited by 704 · cited 1×
“There is some evidence that the response to treatment is suboptimal in those who adhere poorly [141, 142].”
BackgroundSelf-citationHoelzel, W., Weykamp, C., Jeppsson, J.-O., Miedema, K., Barr, J. R., Goodall, I., Hoshino, T., John, W. G., Kobold, U., Little, R., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.024802 · Cited by 690
Treatment of postmenopausal osteoporosis
Delmas, P. D. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08827-x · Cited by 681
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for Osteoporosis
Black, D. M., Bilezikian, J. P., Ensrud, K. E., Greenspan, S. L., Palermo, L., Hue, T., Lang, T. F., McGowan, J. A., & Rosen, C. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050336 · Cited by 614
Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate
Eastell, R., Barton, I., Hannon, R., Chines, A., Garnero, P., & Delmas, P. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1051 · Cited by 588 · cited 2×
“In the VERT study, the change in u-CTX and u-NTX at 3 to 6 months explained between 54% and 77% of the fracture risk reduction with risedronate, depending on the marker, the method of analysis and the fracture type [123].”
MethodSelf-citationMacLean, C., Newberry, S., Maglione, M., McMahon, M., Ranganath, V., Suttorp, M., Mojica, W., Timmer, M., Alexander, A., McNamara, M., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-3-200802050-00198 · Cited by 529
Requirements for DXA for the management of osteoporosis in Europe
Kanis, J. A., & Johnell, O. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1811-2 · Cited by 495 · cited 3×
“[5 2] H aw ai i, 51 2 co m m un ity”
BackgroundSelf-citationSerum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.
Szulc, P., Chapuy, M. C., Meunier, P. J., & Delmas, P. D. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116387 · Cited by 484 · cited 1×
“For example, s-OC is variously a strong [56, 62], moderate [55, 63], borderline [49, 50] or non-significant [47, 51, 58–60, 68] predictor of fracture risk.”
BackgroundHochberg, M. C. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1586 · Cited by 480 · cited 1×
“improved bone microarchitecture) that might be captured in the measurement of BTMs, but not by BMD [27, 122].”
BackgroundKhosla, S. (1998) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2266 · Cited by 447 · cited 1×
“There is a negative correlation between BMD and BTMs, which becomes stronger with advancing age [50, 69–71].”
BackgroundSarkar, S., Mitlak, B. H., Wong, M., Stock, J. L., Black, D. M., & Harper, K. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.1.1 · Cited by 442 · cited 1×
“For example, the change in spine BMD over 3 years explained only 11% of the reduction in spine fracture risk with alendronate [119], 18% for risedronate [120] and close to zero for raloxifene [121].”
BackgroundGreenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., Blosch, C. M., Mathisen, A. L., Morris, S. A., Marriott, T. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-5-200703060-00005 · Cited by 427
Self-citationEffects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women
Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & San Martin, J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 425 · cited 1×
“−50 −72 Bone [99] 60 mg/6 months, s.”
Bauer, D. C., Black, D. M., Garnero, P., Hochberg, M., Ott, S., Orloff, J., Thompson, D. E., Ewing, S. K., Delmas, P. D., & for the Fracture Intervention Trial Study Group (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040512 · Cited by 405 · cited 3×
“The BTMs were not always collected in the correct way—the s-CTX samples from FIT were mostly non-fasting [126] and the u-CTX samples from MORE were on first morning void (not the usual second morning void) [125].”
BackgroundSelf-citationCompston, J., Cooper, A., Cooper, C., Francis, R., Kanis, J. A., Marsh, D., McCloskey, E. V., Reid, D. M., Selby, P., & Wilkins, M. (2009) · Maturitas · doi:10.1016/j.maturitas.2008.11.022 · Cited by 403
Self-citationIdentification of Osteopenic Women at High Risk of Fracture: The OFELY Study
Sornay-Rendu, E., Munoz, F., Garnero, P., Duboeuf, F., & Delmas, P. D. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050609 · Cited by 394 · cited 1×
“Several studies have reported that in women with a low BMD, the presence of increased BTMs has an additive effect on fracture risk [49–55].”
BackgroundSelf-citationVergnaud, P., Garnero, P., Meunier, P. J., Bréart, G., Kamihagi, K., & Delmas, P. D. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3805 · Cited by 389 · cited 3×
“For example, s-OC is variously a strong [56, 62], moderate [55, 63], borderline [49, 50] or non-significant [47, 51, 58–60, 68] predictor of fracture risk.”
BackgroundResultSelf-citationRiggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380 · cited 1×
“These changes in BTMs following antiresorptive therapy are followed by an increase in BMD, assumed to be related to the decrease in bone turnover and the consequences therefrom [78].”
BackgroundPREDICTION OF RAPID BONE LOSS IN POSTMENOPAUSAL WOMEN
Christiansen, C., Riis, B. J., & Rødbro, P. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91671-0 · Cited by 364 · cited 2×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundGreenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R. S., Zanchetta, J., Blosch, C. M., Mathisen, A. L., Morris, S. A., & Marriott, T. B. (2007) · Annals of Internal Medicine · Cited by 360
Rosen, C. J., Hochberg, M. C., Bonnick, S. L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Petruschke, R. A., Thompson, D. E., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040920 · Cited by 345 · cited 1×
“Hannon [92] 10 mg/day −71 −27 Rosen [91] 70 mg/week −64 −41 −74 −53”
Self-citationA New Approach to the Development of Assessment Guidelines for Osteoporosis
Kanis, J. A., Black, D., Cooper, C., Dargent, P., Dawson-Hughes, B., De Laet, C., Delmas, P., Eisman, J., Johnell, O., Jonsson, B., et al. (2002) · Osteoporosis International · doi:10.1007/s001980200069 · Cited by 338
Self-citationBone, H. G., McClung, M. R., Roux, C., Recker, R. R., Eisman, J. A., Verbruggen, N., Hustad, C. M., DaSilva, C., Santora, A. C., & Ince, B. A. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091035 · Cited by 335 · cited 1×
“Odanacatib is a cathepsin K inhibitor that is in phase III development which inhibits bone resorption as judged by s-CTX [106] but has no clear effect on TRACP.”
BackgroundSelf-citationClowes, J. A., Peel, N. F. A., & Eastell, R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030501 · Cited by 334
Self-citationMiller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Self-citationLewiecki, E. M., Miller, P. D., McClung, M. R., Cohen, S. B., Bolognese, M. A., Liu, Y., Wang, A., Siddhanti, S., & Fitzpatrick, L. A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070809 · Cited by 319 · cited 1×
“−60 75 −38 Lewiecki [100] 60 mg/6 months, s.”
Self-citationChen, P., Satterwhite, J. H., Licata, A. A., Lewiecki, E. M., Sipos, A. A., Misurski, D. M., & Wagman, R. B. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050105 · Cited by 311 · cited 3×
“It is possible that the Fracture Prevention Trial was negative because the BTM substudy was too small [118].”
BackgroundDelmas, P. D., & Seeman, E. (2004) · Bone · doi:10.1016/j.bone.2003.12.022 · Cited by 294 · cited 2×
“improved bone microarchitecture) that might be captured in the measurement of BTMs, but not by BMD [27, 122].”
BackgroundBiochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly Women
Gerdhem, P., Ivaska, K. K., Alatalo, S. L., Halleen, J. M., Hellman, J., Isaksson, A., Pettersson, K., Väänänen, H. K., Åkesson, K., & Obrant, K. J. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301244 · Cited by 283 · cited 3×
“The prediction of BTMs for fracture was independent of BMD in some studies [49, 51, 55, 64] but not in all studies [61, 66].”
BackgroundResult(1965) · The Lancet · doi:10.1016/s0140-6736(65)92685-1 · Cited by 283
Chesnut, C. H., Bell, N. H., Clark, G. S., Drinkwater, B. L., English, S. C., Johnston, C. C., Notelovitz, M., Rosen, C., Cain, D. F., Flessland, K. A., et al. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00387-7 · Cited by 282 · cited 1×
“For example, the increase in spine BMD in response to HRT is greater in those with higher u-NTX at baseline [31].”
BackgroundDietary calcium, physical activity, and risk of hip fracture: a prospective study.
Wickham, C. A., Walsh, K., Cooper, C., Barker, D. J., Margetts, B. M., Morris, J., & Bruce, S. A. (1989) · BMJ · doi:10.1136/bmj.299.6704.889 · Cited by 280 · cited 1×
“We excluded studies that did not provide separate data for men and women [25] or did not provide separate data on hip fractures [26].”
ResultSelf-citation(BONE), F. T. O. I. O. V. F. T. I. N. A. A. E., Delmas, P. D., Recker, R. R., Chesnut, C. H., Skag, A., Stakkestad, J. A., Emkey, R., Gilbride, J., Schimmer, R. C., & Christiansen, C. (2004) · Osteoporosis International · doi:10.1007/s00198-004-1602-9 · Cited by 279 · cited 1×
“Ibandronate Delmas [94] 2.”
Riis, B. J., Hansen, M. A., Jensen, A. M., Overgaard, K., & Christiansen, C. (1996) · Bone · doi:10.1016/8756-3282(96)00102-0 · Cited by 277
The degree of mineralization is a determinant of bone strength: a study on human calcanei
Follet, H., Boivin, G., Rumelhart, C., & Meunier, P. J. (2004) · Bone · doi:10.1016/j.bone.2003.12.012 · Cited by 269 · cited 1×
“In addition, increased bone turnover increases the proportion of recently synthesised bone which is less well mineralised than mature bone [43] with fewer enzymatic post-translational modifications of bone collagen (cross-linking and β-isomerisation) [44, 45].”
BackgroundBanse, X., Sims, T. J., & Bailey, A. J. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.9.1621 · Cited by 267 · cited 1×
“In addition, increased bone turnover increases the proportion of recently synthesised bone which is less well mineralised than mature bone [43] with fewer enzymatic post-translational modifications of bone collagen (cross-linking and β-isomerisation) [44, 45].”
BackgroundBone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women
Štěpán, J. J., Pospíchal, J., Presl, J., & Pacovský, V. (1987) · Bone · doi:10.1016/8756-3282(87)90002-0 · Cited by 264 · cited 1×
“There is a negative correlation between BMD and BTMs, which becomes stronger with advancing age [50, 69–71].”
BackgroundDelmas, P. D., Adami, S., Strugala, C., Stakkestad, J. A., Reginster, J., Felsenberg, D., Christiansen, C., Civitelli, R., Drezner, M. K., Recker, R. R., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21918 · Cited by 258 · cited 2×
“5 mg/day −34 −31 Delmas [95] 2.”
Hannon, R., Blumsohn, A., Naylor, K., & Eastell, R. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.7.1124 · Cited by 257
Self-citationPreanalytical Variability of Biochemical Markers of Bone Turnover
Hannon, R., & Eastell, R. (2000) · Osteoporosis International · doi:10.1007/s001980070004 · Cited by 245 · cited 1×
“Limitations variously include their biological variability (Table 1) [14] and, in some cases, the multiple methodologies used for the same analyte (e.”
MethodSelf-citationRapid Bone Loss Is Associated with Increased Levels of Biochemical Markers
Dr. Ross, P. D., & Knowlton, W. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.2.297 · Cited by 243 · cited 2×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundBjarnason, N. H., Sarkar, S., Duong, T., Mitlak, B., Delmas, P. D., & Christiansen, C. (2001) · Osteoporosis International · doi:10.1007/s001980170020 · Cited by 230
Watts, N. B., Cooper, C., Lindsay, R., Eastell, R., Manhart, M. D., Barton, I. P., van Staa, T.-P., & Adachi, J. D. (2004) · Journal of Clinical Densitometry · doi:10.1385/jcd:7:3:255 · Cited by 229 · cited 1×
“For example, the change in spine BMD over 3 years explained only 11% of the reduction in spine fracture risk with alendronate [119], 18% for risedronate [120] and close to zero for raloxifene [121].”
BackgroundSelf-citationArlot, M., Meunier, P. J., Boivin, G., Haddock, L., Tamayo, J., Correa-Rotter, R., Jasqui, S., Donley, D. W., Dalsky, G. P., Martin, J. S., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050309 · Cited by 226 · cited 1×
“4 Changes (% ± SEM) in markers of bone resorption (NTX) and bone formation (PINP) following treatment with an anti-resorptive therapy (alendronate) and an anabolic therapy (teriparatide), redrawn from [79] Osteoporos Int”
BackgroundRosen, C. J., Chesnut, C. H., & Mallinak, N. J. S. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.6.4004 · Cited by 225
Szulc, P., & Delmas, P. D. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0660-9 · Cited by 220 · cited 3×
“In addition, there are other mechanisms whereby increased bone turnover might be associated with an increased fracture risk independent of BMD [12].”
BackgroundMethodBone turnover markers: understanding their value in clinical trials and clinical practice
Civitelli, R., Armamento-Villareal, R., & Napoli, N. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0838-9 · Cited by 216 · cited 3×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundMethodViguet-Carrin, S., Roux, J. P., Arlot, M. E., Merabet, Z., Leeming, D. J., Byrjalsen, I., Delmas, P. D., & Bouxsein, M. L. (2006) · Bone · doi:10.1016/j.bone.2006.05.013 · Cited by 214 · cited 1×
“In addition, increased bone turnover increases the proportion of recently synthesised bone which is less well mineralised than mature bone [43] with fewer enzymatic post-translational modifications of bone collagen (cross-linking and β-isomerisation) [44, 45].”
BackgroundSarkar, S., Reginster, J.-Y., Crans, G. G., Diez-Perez, A., Pinette, K. V., & Delmas, P. D. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301243 · Cited by 210 · cited 2×
“The BTMs were not always collected in the correct way—the s-CTX samples from FIT were mostly non-fasting [126] and the u-CTX samples from MORE were on first morning void (not the usual second morning void) [125].”
BackgroundSerum Bone Alkaline Phosphatase and Calcaneus Bone Density Predict Fractures: A Prospective Study
Ross, P. D., Kress, B. C., Parson, R. E., Wasnich, R. D., Armour, K. A., & Mizrahi, I. A. (2000) · Osteoporosis International · doi:10.1007/s001980050009 · Cited by 207 · cited 1×
“Several studies have reported that in women with a low BMD, the presence of increased BTMs has an additive effect on fracture risk [49–55].”
BackgroundBone turnover markers in the management of postmenopausal osteoporosis
Brown, J. P., Albert, C., Nassar, B. A., Adachi, J. D., Cole, D., Davison, K. S., Dooley, K. C., Don-Wauchope, A., Douville, P., Hanley, D. A., et al. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.04.001 · Cited by 204 · cited 2×
“" Multidisciplinary working group under the auspices of the Scientific Advisory Council of Osteoporosis Canada [11] Bone turnover markers in the management of postmenopausal osteoporosis (review— endorsed by several national societies) Possible algorithm: measure at baseline s-CTX (antiresorptive therapy) and Total s-…”
BackgroundBiology of the basic multicellular unit and the pathophysiology of osteoporosis
Jilka, R. L. (2003) · Medical and Pediatric Oncology · doi:10.1002/mpo.10334 · Cited by 203 · cited 1×
“Oestrogen deficiency, associated with menopause, results in a generalised increase in bone remodelling and an imbalance between bone formation and resorption [28, 29].”
BackgroundVergnaud, P. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.719 · Cited by 202
Luukinen, H., Käkönen, S.-M., Pettersson, K., Koski, K., Laippala, P., Lövgren, T., Kivelä, S.-L., & Väänänen, H. K. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.12.2473 · Cited by 197 · cited 3×
“In a study of elderly men in northern Finland, a decrease in carboxylated s-OC/total s-OC ratio was associated with increased risk of subsequent fractures [58].”
BackgroundBiochemical Indices of Bone Turnover and the Assessment of Fracture Probability
Johnell, O., Odén, A., De Laet, C., Garnero, P., Delmas, P. D., & Kanis, J. A. (2002) · Osteoporosis International · doi:10.1007/s001980200068 · Cited by 196 · cited 3×
“There has been no study in which subjects were stratified according to BTMs and then randomised to treatment or placebo; results from such studies would be of interest [67].”
BackgroundMethodInfluentialSelf-citationvan Daele, P. L. A., Seibel, M. J., Burger, H., Hofman, A., Grobbee, D. E., van Leeuwen, J. P. T. M., Birkenhager, J. C., & Pols, H. A. P. (1996) · BMJ · doi:10.1136/bmj.312.7029.482 · Cited by 194 · cited 13×
“Relative risk (95% CI) adjusted to age, presence of prevalent fracture and physical activity Levels >2 SD of premenopausal women s-OC RR=1.5 (0.8–2.7) d p=0.20 RR=1.5 (0.8–2.7) e p=0.20 s-BALP RR=2.4 (1.3–4.2) d p=0.005 RR=1.9 (1.13–3.4) e p=0.03 s-PICP RR=1.3 (0.7–2.5) d p=0.40 RR=1.7 (0.7–2.5) e p=0.43 s-PINP RR=1.3…”
BackgroundMethodInfluentialGarnero, P., Borel, O., & Delmas, P. D. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.4.694 · Cited by 193
Self-citationBauer, D. C., Garnero, P., Hochberg, M. C., Santora, A., Delmas, P., Ewing, S. K., & Black, D. M. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051018 · Cited by 190 · cited 2×
“In the FIT, the non-spine fracture efficacy of alendronate was greater in women with higher s-PINP before treatment, suggesting that bisphosphonate treatment may be most effective in women with elevated bone turnover [132].”
BackgroundSelf-citationHansen, M. A., Overgaard, K., Riis, B. J., & Christiansen, C. (1991) · Osteoporosis International · doi:10.1007/bf01880450 · Cited by 188 · cited 1×
“It was considered that a low BMD along with a high rate of bone loss might help identify those who would benefit most from hormone replacement therapy (HRT) [134].”
BackgroundDevelopment and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™)
Fujiwara, S., Nakamura, T., Orimo, H., Hosoi, T., Gorai, I., Oden, A., Johansson, H., & Kanis, J. A. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0544-4 · Cited by 188
Self-citationDelmas, P. D., Vrijens, B., Eastell, R., Roux, C., Pols, H. A. P., Ringe, J. D., Grauer, A., Cahall, D., Watts, N. B., & on behalf of the Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1526 · Cited by 186
Self-citationA Revised Clinician’s Guide to the Prevention and Treatment of Osteoporosis
Dawson-Hughes, B., & on behalf of the National Osteoporosis Foundation Guide Committee (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0926 · Cited by 180
Rapid and robust response of biochemical markers of bone formation to teriparatide therapy
Glover, S. J., Eastell, R., McCloskey, E. V., Rogers, A., Garnero, P., Lowery, J., Belleli, R., Wright, T. M., & John, M. R. (2009) · Bone · doi:10.1016/j.bone.2009.07.091 · Cited by 176 · cited 1×
“−60 −70 −60 Teriparatide Glover [101] 20 μg/day +111 +76 +18 +5 +8 +3”
Self-citationThe Contribution of Trabecular Architecture to Cancellous Bone Quality
Dempster, D. W. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.20 · Cited by 170 · cited 1×
“For example, resorption cavities on either side of a trabeculum give rise to stress concentrators that result in the local weakening of the trabeculum that is disproportionate to the small amount of bone lost [42].”
BackgroundBauer, D. C., Sklarin, P. M., Stone, K. L., Black, D. M., Nevitt, M. C., Ensrud, K. E., Arnaud, C. D., Genant, H. K., Garnero, P., Delmas, P. D., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.8.1404 · Cited by 170 · cited 1×
“For example, s-OC is variously a strong [56, 62], moderate [55, 63], borderline [49, 50] or non-significant [47, 51, 58–60, 68] predictor of fracture risk.”
BackgroundSelf-citationBone Resorption and Osteoporotic Fractures in Elderly Men: The Dubbo Osteoporosis Epidemiology Study
Meier, C., Nguyen, T. V., Center, J. R., Seibel, M. J., & Eisman, J. A. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041207 · Cited by 169 · cited 2×
“The prediction of BTMs for fracture was independent of BMD in some studies [49, 51, 55, 64] but not in all studies [61, 66].”
BackgroundResultGlover, S. J., Gall, M., Schoenborn-Kellenberger, O., Wagener, M., Garnero, P., Boonen, S., Cauley, J. A., Black, D. M., Delmas, P. D., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080703 · Cited by 167
Self-citationLeeming, D. J., Alexandersen, P., Karsdal, M. A., Qvist, P., Schaller, S., & Tankó, L. B. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0174-3 · Cited by 160 · cited 3×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundMethodSerum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women:
Chapurlat, R. D., Garnero, P., Brárt, G., Meunier, P. J., & Delmas, P. D. (2000) · Bone · doi:10.1016/s8756-3282(00)00325-2 · Cited by 159 · cited 1×
“Surprisingly, it was the afternoon level of CTX that was more closely related to fracture risk than the morning sample in the one study in which this was examined [57].”
BackgroundSelf-citationEstablishing a reference range for bone turnover markers in young, healthy women
Glover, S. J., Garnero, P., Naylor, K. E., Rogers, A., & Eastell, R. (2008) · Bone · doi:10.1016/j.bone.2007.12.218 · Cited by 159
Self-citationIvaska, K. K., Gerdhem, P., Väänänen, H. K., Åkesson, K., & Obrant, K. J. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.091006 · Cited by 157 · cited 2×
“Logarithmic transformation has been used in a minority of studies, presumably to normalise the distribution of the measurement [12, 62, 65].”
BackgroundMethodGarnero, P., Vergnaud, P., & Hoyle, N. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.094953 · Cited by 157
Self-citationBergmann, P., Body, J.-J., Boonen, S., Boutsen, Y., Devogelaer, J.-P., Goemaere, S., Kaufman, J.-M., Reginster, J.-Y., Gangji, V., & Members of the Advisory Board on Bone Markers (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01911.x · Cited by 154 · cited 2×
“" Belgian Bone Club [9] Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis 2009 Canada " Potential clinical uses of BTMs include prediction of bone loss and fracture in untreated postmenopausal women, to monitor oste…”
BackgroundHannon, R. A., Clowes, J. A., Eagleton, A. C., Hadari, A. A., Eastell, R., & Blumsohn, A. (2003) · Bone · doi:10.1016/j.bone.2003.04.002 · Cited by 154
Self-citationA method to assess the proportion of treatment effect explained by a surrogate endpoint
Li, Z., Meredith, M. P., & Hoseyni, M. S. (2001) · Statistics in Medicine · doi:10.1002/sim.984 · Cited by 153
Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study
Bauer, D. C., Garnero, P., Harrison, S. L., Cauley, J. A., Eastell, R., Ensrud, K. E., & Orwoll, E. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090526 · Cited by 147 · cited 2×
“In the US MrOS study, hip and non-spine fractures were associated with increased s-PINP and s-CTX, an association no longer evident after adjustment for hip BMD [66].”
BackgroundResultSelf-citationA Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women1
Prestwood, K. M., Gunness, M., Muchmore, D. B., Lu, Y., Wong, M., & Raisz, L. G. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6654 · Cited by 139 · cited 1×
“HRT, oral CEE Prestwood [88] 0.”
Predictors of Fractures in Elderly Women
Tromp, A. M., Ooms, M., Popp‐Snijders, C., Roos, J. C., & Lips, P. T. A. M. (2000) · Osteoporosis International · doi:10.1007/pl00004174 · Cited by 139 · cited 2×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundResultMelton, L. J., Crowson, C. S., O'Fallon, W. M., Wahner, H. W., & Riggs, B. L. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.2.312 · Cited by 138 · cited 1×
“For example, s-OC is variously a strong [56, 62], moderate [55, 63], borderline [49, 50] or non-significant [47, 51, 58–60, 68] predictor of fracture risk.”
BackgroundMean wall thickness and formation periods of trabecular bone packets in idiopathic osteoporosis
Darby, A. J., & Meunier, P. J. (1981) · Calcified Tissue International · doi:10.1007/bf02409438 · Cited by 136 · cited 1×
“Oestrogen deficiency, associated with menopause, results in a generalised increase in bone remodelling and an imbalance between bone formation and resorption [28, 29].”
BackgroundChanges in bone mass and bone turnover following tibial shaft fracture
Veitch, S. W., Findlay, S. C., Hamer, A. J., Blumsohn, A., Eastell, R., & Ingle, B. M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-2025-y · Cited by 136 · cited 1×
“In the FIT study, the fractures were only counted if they occurred after the BTM sample was taken [133].”
Self-citationGarnero, P., Cloos, P., Sornay-Rendu, E., Qvist, P., & Delmas, P. D. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.5.826 · Cited by 133 · cited 1×
“The prediction of BTMs for fracture was independent of BMD in some studies [49, 51, 55, 64] but not in all studies [61, 66].”
ResultSelf-citationFRAX® assessment of osteoporotic fracture probability in Switzerland
Lippuner, K., Johansson, H., Kanis, J. A., & Rizzoli, R. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0975-1 · Cited by 129
Self-citationThienpont, L. M., Van Uytfanghe, K., Beastall, G., Faix, J. D., Ieiri, T., Miller, W. G., Nelson, J. C., Ronin, C., Ross, H. A., Thijssen, J. H., et al. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2009.140178 · Cited by 128
Risk Factors for Perimenopausal Fractures: A Prospective Study
Huopio, J., Kröger, H., Honkanen, R., Saarikoski, S., & ALHAVA, E. M. (2000) · Osteoporosis International · doi:10.1007/s001980050284 · Cited by 125 · cited 1×
“We excluded studies that did not provide separate data for men and women [25] or did not provide separate data on hip fractures [26].”
ResultSeibel, M. J., Naganathan, V., Barton, I. P., & Grauer, A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301231 · Cited by 121 · cited 1×
“In the study of risedronate [137], a higher baseline u-DPD (total) was associated with a greater gain in spine BMD in the first year, but it was not related to greater fracture risk reduction.”
BackgroundDelmas, P. D., Munoz, F., Black, D. M., Cosman, F., Boonen, S., Watts, N. B., Kendler, D., Eriksen, E. F., Mesenbrink, P. G., & Eastell, R. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090310 · Cited by 120
Self-citationDevelopment of an algorithm for using PINP to monitor treatment of patients with teriparatide
Eastell, R., Krege, J. H., Chen, P., Glass, E. V., & Reginster, J.-Y. (2006) · Current Medical Research and Opinion · doi:10.1185/030079905x75096 · Cited by 120 · cited 1×
“Thus, their measurement usually enables the identification of most responders to treatment using the LSC approach [114, 116].”
MethodSelf-citationSaag, K. G., Lindsay, R., Kriegman, A. G., Beamer, E., & Zhou, W. (2007) · Bone · doi:10.1016/j.bone.2007.01.016 · Cited by 118 · cited 1×
“6 The time course of s-CTX (mean ± SEM) following treatment with the bisphosphonate alendronate given weekly by mouth and zoledronic acid (zoledronate) given as a single intravenous dose, redrawn from [82] Osteoporos Int”
MethodReginster, J., Sarkar, S., Zegels, B., Henrotin, Y. E., Bruyère, O., Agnusdei, D., & Collette, J. (2003) · Bone · doi:10.1016/j.bone.2003.10.004 · Cited by 115
Self-citationMarcus, R., Holloway, L., Wells, B., Greendale, G., James, M. K., Wasilauskas, C., & Kelaghan, J. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1583 · Cited by 114 · cited 1×
“There is a negative correlation between BMD and BTMs, which becomes stronger with advancing age [50, 69–71].”
BackgroundDeterminants of Bone Turnover Markers in Healthy Premenopausal Women
Adami, S., Bianchi, G., Brandi, M. L., Giannini, S., Ortolani, S., DiMunno, O., Frediani, B., Rossini, M., & On behalf of the BONTURNO study group (2008) · Calcified Tissue International · doi:10.1007/s00223-008-9126-5 · Cited by 113
Screening procedure for women at risk of developing postmenopausal osteoporosis
Christiansen, C., Riis, B. J., & Rødbro, P. (1990) · Osteoporosis International · doi:10.1007/bf01880414 · Cited by 113
Rosen, C. J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.6.1904 · Cited by 112
Åkesson, K., Ljunghall, S., Jonsson, B., Sernbo, I., Johnell, O., Gärdsell, P., & Obrant, K. J. (1995) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650101127 · Cited by 111 · cited 7×
“Relative risk (95% CI) adjusted to age, presence of prevalent fracture and physical activity Levels >2 SD of premenopausal women s-OC RR=1.5 (0.8–2.7) d p=0.20 RR=1.5 (0.8–2.7) e p=0.20 s-BALP RR=2.4 (1.3–4.2) d p=0.005 RR=1.9 (1.13–3.4) e p=0.03 s-PICP RR=1.3 (0.7–2.5) d p=0.40 RR=1.7 (0.7–2.5) e p=0.43 s-PINP RR=1.3…”
BackgroundResultInfluentialInterlaboratory Variation of Biochemical Markers of Bone Turnover
Seibel, M. J., Lang, M., & Geilenkeuser, W. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.8.1443 · Cited by 110 · cited 3×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundTraceability as a unique tool to improve standardization in laboratory medicine
Panteghini, M. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2008.09.098 · Cited by 104 · cited 1×
“In this way, all routine measurements can be traced to the primary reference material [154, 155].”
BackgroundA cross-sectional study of bone turnover markers in healthy premenopausal women
de Papp, A. E., Bone, H. G., Caulfield, M. P., Kagan, R., Buinewicz, A., Chen, E., Rosenberg, E., & Reitz, R. E. (2007) · Bone · doi:10.1016/j.bone.2007.01.008 · Cited by 104
Bone Density Change and Biochemical Indices of Skeletal Turnover
Cosman, F., Nieves, J. W., Wilkinson, C., Schnering, D., Shen, V., & Lindsay, R. (1996) · Calcified Tissue International · doi:10.1007/bf02508642 · Cited by 104 · cited 2×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundGreenspan, S. L., Resnick, N. M., & Parker, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1091 · Cited by 103 · cited 1×
“5) [117] and for anabolic therapy [118].”
Delmas, P. D., Licata, A., Reginster, J., Crans, G., Chen, P., Misurski, D. A., Wagman, R. B., & Mitlak, B. (2006) · Bone · doi:10.1016/j.bone.2006.02.003 · Cited by 102 · cited 1×
“However, the baseline BTM did not predict the relative fracture risk reduction with teriparatide [138].”
BackgroundImplementation of Reference Systems in Laboratory Medicine
Müller, M. M. (2000) · Clinical Chemistry · doi:10.1093/clinchem/46.12.1907 · Cited by 99 · cited 1×
“Standardisation and the establishment of a reference system [147] for the BTMs is the route to achieve this.”
BackgroundVasikaran, S. D. (2008) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360801949442 · Cited by 97
Self-citationChristenson, R. H. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.068437 · Cited by 94 · cited 1×
“However a considerable body of knowledge has been developed on these issues in recent years [156].”
BackgroundBerry, S. D., Kiel, D. P., Donaldson, M. G., Cummings, S. R., Kanis, J. A., Johansson, H., & Samelson, E. J. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1127-3 · Cited by 87 · cited 1×
“Since the availability of FRAX, treatment decisions in the management of osteoporosis are increasingly being based on the assessment of a patient’s probability of sustaining a fragility fracture [8, 21, 73–77].”
BackgroundSelf-citationReference measurement systems in clinical chemistry
Thienpont, L. M., Uytfanghe, K. V., & Leenheer, A. P. D. (2002) · Clinica Chimica Acta · doi:10.1016/s0009-8981(02)00188-2 · Cited by 79 · cited 1×
“Standardisation of measurement requires the development of a reference measurement system for each BTM, the components of which are as follows [153]: Where possible, the marker (the measurand) should be clearly defined by molecular structure and weight.”
Finigan, J., Greenfield, D. M., Blumsohn, A., Hannon, R. A., Peel, N. F., Jiang, G., & Eastell, R. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070814 · Cited by 78 · cited 1×
“An increased rate of bone loss from the forearm and hip is associated with an increase in the risk of vertebral fracture [40, 41], an effect independent of final BMD.”
BackgroundSelf-citationEastell, R., Hannon, R. A., Garnero, P., Campbell, M. J., & Delmas, P. D. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.07090b · Cited by 76 · cited 1×
“In the VERT study [131], the fracture risk was at its lowest when the uCTX level was below a critical point that was equivalent to the mean value for premenopausal women.”
BackgroundSelf-citationTraceability, reference systems and result comparability.
Panteghini, M. (2007) · PubMed · Cited by 76
Blouin, J., Dragomir, A., Moride, Y., Ste‐Marie, L., Fernandes, J., & Perreault, S. (2008) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2008.03178.x · Cited by 61 · cited 1×
“There is some evidence that the response to treatment is suboptimal in those who adhere poorly [141, 142].”
BackgroundBruyère, O., Collette, J., Delmas, P. D., Rouillon, A., Roux, C., Seidel, L., Richy, F. F., & Reginster, J. (2003) · Maturitas · doi:10.1016/s0378-5122(03)00042-2 · Cited by 56
Self-citationFoged, N. T., Delaissé, J., Peng, H., Lou, H., Sato, T., Winding, B., & Bonde, M. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110212 · Cited by 56 · cited 1×
“Of course, the peptides in the serum that cross-react with such antibodies have a wide range of molecular weights [145].”
BackgroundBone markers : biochemical and clinical perspectives
Eastell, R. (2001) · Martin Dunitz eBooks · Cited by 55
Self-citationStandardization of troponin I measurements: an update
Panteghini, M., Bunk, D. M., Christenson, R. H., Katrukha, A., Porter, R., Schimmel, H. G., Wang, L., & Tate, J. R. (2008) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.291 · Cited by 54
Dobnig, H., Piswanger-Sölkner, J. C., Obermayer-Pietsch, B. M., Tiran, A., Groselj‐Strele, A., Maier, E., Maritschnegg, P., Riedmüller, G., Brueck, C. C., & Fahrleitner‐Pammer, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2079 · Cited by 53 · cited 3×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundResultA Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women
Prestwood, K. M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.6.2197 · Cited by 53
Bone markers: biochemical and clinical perspectives.
REEVE, J. (2002) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.84b6.0840933 · Cited by 51
Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black, D. M., Bouxsein, M., Palermo, L., McGowan, J., Newitt, D. C., Rosen, E., Majumdar, S., & Rosen, C. J. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2781 · Cited by 47 · cited 1×
“PTH 1–84 Greenspan [102] 100 μg/day +90 +140 Black [103] 100 μg/day +90 +20 +10”
Rogers, A., Glover, S. J., & Eastell, R. (2009) · Bone · doi:10.1016/j.bone.2009.07.089 · Cited by 46 · cited 1×
“Thus, their measurement usually enables the identification of most responders to treatment using the LSC approach [114, 116].”
MethodSelf-citationReference material for PSA: the IFCC standardization study
Stamey, T. A., Chen, Z., & Prestigiacomo, A. F. (1998) · Clinical Biochemistry · doi:10.1016/s0009-9120(98)00055-1 · Cited by 44 · cited 1×
“IFCC has an extensive experience with this process [148–152].”
BackgroundBruyère, O., Collette, J., Rizzoli, R., Decock, C., Ortolani, S., Cormier, C., Detilleux, J. C., & Reginster, J.-Y. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1078-8 · Cited by 43 · cited 1×
“Calcitonin Chesnut [83] 200 IU/day, intranasal −10 Strontium ranelate Meunier [84] 2 g/day +8 −12 Bruyère [85] −11”
Self-citationGast, M. W., van Gils, C. H., Wessels, L. F. A., Harris, N., Bonfrèr, J. M. G., Rutgers, E. J. T., Schellens, J. H. M., & Beijnen, J. H. (2009) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2009.151 · Cited by 42
Emkey, R. D., Delmas, P. D., Bolognese, M. A., Borges, J. L. C., Cosman, F., Ragi-Eis, S., Recknor, C. P., Zerbini, C. A. F., Neate, C., Sedarati, F., et al. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.04.018 · Cited by 41 · cited 1×
“Emkey [93] 70 mg/week −68 −81”
Blouin, J., Dragomir, A., Ste‐Marie, L., Fernandes, J., & Perreault, S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1856 · Cited by 40 · cited 1×
“Adherence to treatment is poor in all chronic diseases; osteoporosis is no exception [140].”
BackgroundOsteoporosis in postmenopausal women: diagnosis and monitoring.
Nelson, H. D., MORRIS, C. D. W., Kraemer, D. F., Mahon, S. M., Carney, N., Nygren, P., & Helfand, M. (2001) · PubMed Central · Cited by 39
Could Strontium Ranelate Have a Synergistic Role in the Treatment of Osteoporosis?
Blake, G. M., Compston, J. E., & Fogelman, I. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090601 · Cited by 38 · cited 1×
“It may be a weak anti-resorptive drug with anabolic properties, or it may have its most important effects through mechanisms that do not involve remodelling (such as changes to crystal properties) [105].”
BackgroundMole, P. A., Walkinshaw, M. H., Robins, S. P., & Paterson, C. R. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01444.x · Cited by 37 · cited 2×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundREEVE, J., Pearson, J., Mitchell, A., Green, J. R., Nicholls, A. C., Justice, J., Hudson, E., & Klenerman, L. (1995) · Calcified Tissue International · doi:10.1007/bf00298429 · Cited by 35
The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women
Naylor, K. E., Clowes, J. A., Finigan, J., Paggiosi, M., Peel, N. F. A., & Eastell, R. (2009) · Bone · doi:10.1016/j.bone.2009.10.043 · Cited by 34 · cited 2×
“Raloxifene Naylor [86] 60 mg/day −34 −25”
Self-citationThe utility of BMD Z-score diagnostic thresholds for secondary causes of osteoporosis
McKiernan, F. E., Berg, R. L., & Linneman, J. G. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1307-1 · Cited by 34 · cited 1×
“The level of BMD has proven less useful in selecting individuals for further workup for secondary osteoporosis [136].”
BackgroundVertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover
Collette, J., Bruyère, O., Kaufman, J., Lorenc, R. S., Felsenberg, D., Spector, T. D., Díaz Curiel, M., Boonen, S., & Reginster, J. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0940-z · Cited by 32 · cited 1×
“Similarly with strontium ranelate, higher baseline BALP and CTX were associated with greater increases in spine BMD, but no greater reduction in vertebral fracture relative risk [139].”
BackgroundSelf-citationSustained response to intravenous alendronate in postmenopausal osteoporosis
Vasikaran, S. D., Khan, S., McCloskey, E. V., & Kanis, J. А. (1995) · Bone · doi:10.1016/8756-3282(95)00400-9 · Cited by 28 · cited 1×
“More rapid decreases in bone resorption are seen with intravenous alendronate than with the oral formulation [81].”
BackgroundSelf-citationStandardization of Assays for Human Chorionic Gonadotropin
Stenman, U. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.031013 · Cited by 24 · cited 1×
“IFCC has an extensive experience with this process [148–152].”
BackgroundPeichl, P., Griesmacher, A., Pointinger, P., Marteau, R., Hartl, W., Gruber, W., & Bröll, H. (1998) · Calcified Tissue International · doi:10.1007/s002239900450 · Cited by 20 · cited 2×
“s-OC Serum osteocalcin Hydroxyapatite-binding protein exclusively synthesised by osteoblasts and odontoblasts Automated Specificity: specific marker of osteoblast function Manual Subject to rapid degradation in serum leads to heterogeneity of OC fragments: usually measured as intact [1–49] or N-mid [1–43] fragment, or…”
BackgroundSelf-citationPereda, C. A., Hannon, R. A., Naylor, K. E., & Eastell, R. (2002) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2002.01177.x · Cited by 16 · cited 1×
“HRT, oestradiol implant Pereda [89] 25 mg/6 months −35 −15 −15 −40”
Self-citationHarmonization and Standardization of Thyroid Function Tests
Klee, G. G. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.145540 · Cited by 14 · cited 1×
“These data can then be used to correct the bias of various systems in order to obtain a consensus mean and harmonisation of results [157].”
MethodTraceability and standardization of immunoassays: A major challenge
Morris, H. A. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2008.09.005 · Cited by 13 · cited 1×
“In this way, all routine measurements can be traced to the primary reference material [154, 155].”
BackgroundSelf-citation
Research works printed but not linked: 1
- Lorenc R, Głuszko P, Karczmarewicz E, Księżopolska-Orłowska K, Misiorowski W, Franek E, Horst-Sikorska W, Kaleta M, Męczekalski B et al (2007) Recommendations on the diagnosis and treatment of osteoporosis. Reducing the incidence of fractures through effective prevention and treatment. Terapia 9:11–39
Cited by
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
Kanis, J. A., McCloskey, E. V., Johansson, H., Cooper, C., Rizzoli, R., Reginster, J.-Y., & on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) · Osteoporosis International · doi:10.1007/s00198-012-2074-y · Cited by 2,948
“More research is required using standardised analytes before robust evidence-based recommendations can be given [74].”
BackgroundSelf-citationAn overview and management of osteoporosis
Sözen, T., Özışık, L., & Çalık Başaran, N. (2019) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2016.048 · Cited by 2,262
“International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Working Group evaluated BTMs in the prediction of fracture risk and for monitoring treatment; it was recommended that bone formation markers (s-PINP) and bone resorption markers (s-CTX) should…”
MethodEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF), Kanis, J. A., Cooper, C., Rizzoli, R., & Reginster, J.-Y. (2019) · Osteoporosis International · doi:10.1007/s00198-018-4704-5 · Cited by 1,900
“More research is required using standardised analytes before robust evidence-based recommendations can be given [73].”
BackgroundSelf-citationThe clinician's guide to prevention and treatment of osteoporosis
LeBoff, M. S., Greenspan, S. L., Insogna, K. L., Lewiecki, E. M., Saag, K. G., Singer, A. J., & Siris, E. S. (2022) · Osteoporosis International · doi:10.1007/s00198-021-05900-y · Cited by 1,487
“3–6 months of treatment with specific antiresorptive therapies and increased biochemical markers of formation after 1–3 months of specific anabolic therapies have been predictive of greater BMD responses and (in some cases) fracture risk reduction [93, 293].”
BackgroundCamacho, P. M., Petak, S. M., Binkley, N., Diab, D. L., Eldeiry, L. S., Farooki, A., Harris, S. T., Hurley, D. L., Kelly, J., Lewiecki, E. M., et al. (2020) · Endocrine Practice · doi:10.4158/gl-2020-0524suppl · Cited by 1,182
“Although they cannot be used to diagnose osteoporosis, elevated levels can predict more rapid rates of bone loss (71-73) and are associated with increased fracture risk independent of BMD in some studies (74-76).”
Self-citation
Metadata
- Authors
- for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., Trenti, T., Wahl, D. A., Cooper, C., & Kanis, J. A.
- Affiliations
- The University of Western Australia (AU)
- Royal Perth Hospital (AU)
- University of Liège (BE)
- Inserm (FR)
- Innsbruck Medical University (AT)
- University of South Australia (AU)
- University of California, Los Angeles (US)
- International Osteoporosis Foundation (CH)
- Southampton General Hospital (GB)
- University of Sheffield (GB)
- Corresponding author
- Cooper, C.
- ORCID
- Venue
- Osteoporosis International
- Published
- 2010-12-24
- Volume
- 22
- Issue
- 2
- Pages
- 391-420
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2005779589
- Cited by
- 1,212
- References
- 160
- Citations by year
- 2026: 93 · 2025: 79 · 2024: 79 · 2023: 69 · 2022: 94 · 2021: 85 · 2020: 102 · 2019: 99 · 2018: 78 · 2017: 93 · 2016: 80 · 2015: 78 · 2014: 56 · 2013: 51 · 2012: 55
- FWCI
- 40.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10082)
- International Osteoporosis Foundation
- Abbott Diagnostics
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- bone turnover markers, fracture risk prediction, osteoporosis treatment monitoring, C-terminal telopeptide of type I collagen, reference materials, postmenopausal women, bone mineral density, pharmacodynamic monitoring, assay variability, quality control
- MeSH terms
- Adult, Aged, Aged, 80 and over, Algorithms, Female, Humans, Male, Middle Aged, Osteoporosis, Reference Standards, Biomarkers, Bone Density, Osteoporosis, Postmenopausal, Bone Remodeling, Treatment Outcome, Risk Assessment, Osteoporotic Fractures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.